Advanced search
Log in
Press Room
Releases
Multimedia
About
Subscribe
Report from Annual General Meeting of XVIVO Perfusion AB (publ)
5/8/2013 2:30 AM EST
At XVIVO Perfusion’s Annual General Meeting yesterday, May 7, the following, amongst other things, was decided:
• No dividend will be paid for the financial year 2012.
• Re-election of Board members Semmy Rülf, Erik von Schenck, Magnus Nilsson and Fredrik Mattsson and new election of Folke Nilsson and Gösta Johannesson, in accordance with Bure’s proposal. Fredrik Mattsson was re-elected Chairman of the Board.
• Remuneration to the members of the Board shall be SEK 470,000 in total, of which SEK 150,000 is allocated to the Chairman of the Board and SEK 80,000 to each Board member who are not an employee of the company.
• Election of KPMG as auditor, with authorized public accountant Jan Malm as the principal auditor.
• Establishment of nomination committee for the next annual general meeting, in accordance with Bure's proposal.
• Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to take a decision on the issue of a...
Interim report January-March 2013
4/19/2013 7:00 AM EST
Strong sales growth and positive cash flow from operating activities
FIRST QUARTER
• Sales increased by 23 percent in local currency. Sales were the highest ever for an...
Annual report 2012
4/15/2013 8:00 AM EST
Today XVIVO Perfusion is publishing the Annual Report for 2012 (in Swedish). The Annual Report is attached to this press release and will also be available on...
Clarification of XVIVO Perfusion’s rights to Professor Stig Steen’s media for the preservation and evaluation of organs
4/12/2013 5:45 AM EST
Due to the insufficient information that Vivoline Medical has distributed in a Memorandum (including supplementary information that was recently published) ahead of its planned...
Conference call interim report
4/11/2013 5:30 AM EST
Invitation to attend XVIVO Perfusion’s conference call regarding presentation of the interim report for the period January – March, 2013. The presentation will be held in English.
Annual General Meeting of XVIVO Perfusion AB (publ)
4/8/2013 9:00 AM EST
The Annual General Meeting of Xvivo Perfusion AB (publ) will take place on Tuesday May 7, 2013, at 5 p.m. in the company's premises at Mässans gata 10 in Gothenburg. Notice of...
Report on operations 2012
2/19/2013 10:30 AM EST
Continuing growth - now on our own
FOURTH QUARTER
· Sales increased by 10 percent in local currency. Sales were the highest ever for an individual quarter and amounted to...
Conference call on the Report on Operations 2012
2/15/2013 6:30 AM EST
Invitation to attend XVIVO Perfusion’s conference call regarding presentation of the Report on Operations 2012. The presentation will be held in English.
Further lawsuits filed against Vitrolife’s American subsidiary regarding Perfadex
2/7/2013 2:30 AM EST
Further lawsuits have been filed against Vitrolife with regard to Perfadex. As the products were sold before the distribution of XVIVO Perfusion, Vitrolife will also handle the...
New Sales and Marketing Director at XVIVO Perfusion
11/21/2012 2:30 AM EST
Christer de Flon has been appointed as Sales and Marketing Director, with responsibility for all marketing and sales activities within Xvivo Perfusion. He joins the company from...
XVIVO Perfusion receives marketing approval for STEEN Solution™ in Canada.
11/8/2012 7:30 AM EST
The current main focus for XVIVO Perfusion is to gain marketing approval in North America for the company’s unique product, STEEN Solution™, which has the potential to increase...
Summary January-September 2012
11/1/2012 3:30 AM EST
Strong growth – start up and work proceeding according to plan
Xvivo Perfusion can note continued strong sales growth of 22 percent during the third quarter and 23 percent...
Shares in Xvivo Perfusion AB will begin trading on NASDAQ OMX First North on October 8, 2012
10/4/2012 2:30 AM EST
Xvivo Perfusion AB was spun off from Vitrolife AB on October 1, whereby Vitrolife shareholders received one share in Xvivo Perfusion for each share in Vitrolife. Xvivo Perfusion...
SEE ALL NEWS
Xvivo Perfusion
RSS
View more
Tweet
Media
more